Clinical Scope and Observational Overview
 

Since 2013, following the introduction of the regulatory framework governing the clinical use of mesenchymal stem cells (MSCs), our clinic has been operating in the field of advanced cellular and regenerative medicine, applying physician-led, individualized medical approaches within defined clinical indications.
 

Our clinical activity is based on:

• long-standing medical experience,

• advanced laboratory and processing technologies,

• individualized therapeutic planning,

• continuous medical supervision and structured follow-up.
   

All medical approaches are selected exclusively on the basis of individual clinical evaluation and are not intended to replace standard therapies when those remain effective.
 

Clinical Areas Observed in Practice
 

Over the course of our clinical practice, we have managed patients with complex medical conditions across core clinical specialties.
The distribution presented below reflects aggregated observational clinical data and does not represent results from randomized clinical trials.
 

Observed clinical areas include:

• Neurology (48%)
  Complex neurological conditions, including multiple sclerosis, pediatric cerebral palsy, autism spectrum disorders, epilepsy, and other neurodegenerative or neuroinflammatory diseases.

• Rheumatology (15%)
  Systemic and autoimmune conditions such as fibromyalgia, systemic lupus erythematosus, scleroderma, and osteoporosis.

• Pulmonology (12%)
  Chronic respiratory conditions, including post–COVID-19 sequelae and chronic obstructive pulmonary disease (COPD).

• Phthisiology (6%)
  Clinical support in selected cases of drug-resistant pulmonary tuberculosis, within a multidisciplinary medical management framework.

• Endocrinology (6%)
  Selected patients with type 2 diabetes mellitus, evaluated on an individual clinical basis.

• Traumatology and Orthopedics (5%)
  Degenerative and post-traumatic conditions, including osteoarthritis, arthritis, aseptic necrosis, and complications of bone healing.

• Internal Medicine (5%)
  Supportive clinical management of chronic systemic conditions, including chronic hepatitis C, based on specific medical indications.

• Cardiology (2%)
  Selected cases of ischemic heart disease and post-infarction cardiomyopathy, following careful clinical assessment.

• Urology (1%)
  Selected functional disorders evaluated on a strict case-by-case medical basis.

​

Additional Clinical Fields
 

In selected cases, our clinical experience also includes patients managed within other core medical specialties, where clinical appropriateness is confirmed through individual physician assessment.

Each case is evaluated independently to determine medical indication and suitability.
 

Medical Responsibility and Clinical Limitations
 

It is essential to emphasize that:

• the data presented are observational in nature,

• clinical outcomes may vary significantly depending on disease stage, individual biology, and prior treatments,

• no guarantees of outcome are provided,

• no medical approach is proposed without a comprehensive physician-led evaluation.
   

All clinical decisions are based on an individualized risk–benefit assessment conducted by qualified medical professionals.
 

Commitment to Transparency
 

By presenting structured clinical and observational information, we aim to provide patients and their families with a clear and responsible understanding of our medical practice, while adhering to strict ethical standards and avoiding overinterpretation of clinical data.

Responsible medicine is grounded in scientific accuracy, clinical integrity, and transparent communication.